Izzy Thomas-Horton outlines the potential of sustainable aviation fuel (SAF) in driving economic growth and job creation in West Cumbria, where Carbon Neutral Fuels (CNF) is developing a green fuel facility supported by £7.4 million in government funding.
Diabetes represents a huge burden on health systems and sufferers, but accurately monitoring blood sugar levels could help people to take control of their health before more serious issues come to light.
In late September, Germany and England joined forces to propel the industry forward with green hydrogen. Combined with series of other initiatives, Plug sees this declaration as an encouraging signal for the development of the green hydrogen sector.
Bryn Sage, CEO of remote patient monitoring provider Inhealthcare, explains how the company’s digital health technology is helping to ease pressures across the NHS, reduce hospital admissions, and improve patients’ health outcomes.
Multiple sclerosis (MS) is a disease that impacts the central nervous system, affecting everything we do. For many patients, the main question is: how do I confront this life-changing condition?
Secarna Pharmaceuticals, the next-generation antisense drug discovery and development company, is developing novel approaches to successfully target Neuropilin 1 (NRP1), a promising target for the treatment of cancer.
It’s not too late to respond to the challenges of the climate emergency – but only if we fast-track vital engineering skills into our economy before 2030 – The Royal Academy of Engineering explains.
Dr. Stefan Rehm, Managing Director of Hypion GmbH, presents the logic of integrated hydrogen hubs as concept to decarbonise heavy duty road transportation.
Amp X is an innovative digital energy platform using a unique, whole-system approach to address critical issues that exist in the electricity grid as a result of the ongoing energy transition towards a fully decarbonised future.
Leading independent European antisense drug discovery company, Secarna, aims to bring novel and effective antisense therapeutic options to an increasing number of patients. CEO Alexander Gebauer tells us how.
